137 related articles for article (PubMed ID: 33485700)
21. Comparing cytology, colposcopy and human papillomavirus cervical intraepithelial lesion screening methods in women with systemic lupus erythematosus.
García-Carrasco M; Mendoza-Pinto C; Méndez-Martínez S; Rodríguez-Reyes A; Munguía-Realpozo P; Taboada-Cole A; Vallejo-Ruiz V; Etchegaray-Morales I; Jiménez-Herrera R; Juárez-Melchor D; Villanueva-López I
Lupus; 2020 Aug; 29(9):1060-1066. PubMed ID: 32501171
[TBL] [Abstract][Full Text] [Related]
22. Cervical Intraepithelial Neoplasia Grade 3 in a HPV-Vaccinated Patient: A Case Report.
Sladič M; Taneska P; Cvjetičanin B; Velikonja M; Smrkolj V; Smrkolj Š
Medicina (Kaunas); 2022 Feb; 58(3):. PubMed ID: 35334516
[TBL] [Abstract][Full Text] [Related]
23. Cervical intraepithelial neoplasia and human papillomavirus infection among Senegalese women seropositive for HIV-1 or HIV-2 or seronegative for HIV.
Seck AC; Faye MA; Critchlow CW; Mbaye AD; Kuypers J; Woto-Gaye G; Langley C; De EB; Holmes KK; Kiviat NB
Int J STD AIDS; 1994; 5(3):189-93. PubMed ID: 8061090
[TBL] [Abstract][Full Text] [Related]
24. Antagonist-mediated down-regulation of Toll-like receptors increases the prevalence of human papillomavirus infection in systemic lupus erythematosus.
Yu SL; Chan PK; Wong CK; Szeto CC; Ho SC; So K; Yu MM; Yim SF; Cheung TH; Wong MC; Cheung JL; Yeung AC; Li EK; Tam LS
Arthritis Res Ther; 2012 Apr; 14(2):R80. PubMed ID: 22513098
[TBL] [Abstract][Full Text] [Related]
25. Prevalence of human papilloma virus infections and cervical cytological abnormalities among Korean women with systemic lupus erythematosus.
Lee YH; Choe JY; Park SH; Park YW; Lee SS; Kang YM; Nam EJ; Park W; Kwon SR; Bae SC; Kim YJ; Suh CH; Kim HA; Hur NW; Lee J
J Korean Med Sci; 2010 Oct; 25(10):1431-7. PubMed ID: 20890422
[TBL] [Abstract][Full Text] [Related]
26. Human papillomavirus types in cervical dysplasia among young HPV-vaccinated women: Population-based nested case-control study.
Kann H; Hortlund M; Eklund C; Dillner J; Faust H
Int J Cancer; 2020 May; 146(9):2539-2546. PubMed ID: 31868230
[TBL] [Abstract][Full Text] [Related]
27. Persistence and clearance of high-risk human papillomavirus and cervical dysplasia at 1 year in women living with human immunodeficiency virus: a prospective cohort study.
Luckett R; Painter H; Hacker MR; Simon B; Seiphetlheng A; Erlinger A; Eakin C; Moyo S; Kyokunda LT; Esselen K; Feldman S; Morroni C; Ramogola-Masire D
BJOG; 2021 Nov; 128(12):1986-1996. PubMed ID: 34008294
[TBL] [Abstract][Full Text] [Related]
28. HPV vaccines and lupus: current approaches towards preventing adverse immune cross-reactivity.
Bragazzi NL; Bridgewood C; Sharif K; Kamal M; Amital H; Watad A; Shoenfeld Y
Expert Rev Vaccines; 2019 Jan; 18(1):31-42. PubMed ID: 30526148
[TBL] [Abstract][Full Text] [Related]
29. The distribution and pathogenic risk of non-9-valent vaccine covered HPV subtypes in cervical lesions.
Ma M; Zhu J; Yang Y; Wang X; Jin Y; Zhang J; Wu S
Cancer Med; 2022 Mar; 11(6):1542-1552. PubMed ID: 34981653
[TBL] [Abstract][Full Text] [Related]
30. Risk factors associated with the persistence of human papillomavirus after cervical excision in patients with high-grade squamous intra-epithelial neoplasia.
Zang L; Huang J; Zhu J; Hu Y
Eur J Obstet Gynecol Reprod Biol; 2021 Nov; 266():175-181. PubMed ID: 34689015
[TBL] [Abstract][Full Text] [Related]
31. Spectrum of genital human papillomavirus infection in a female adolescent population.
Jamison JH; Kaplan DW; Hamman R; Eagar R; Beach R; Douglas JM
Sex Transm Dis; 1995; 22(4):236-43. PubMed ID: 7482107
[TBL] [Abstract][Full Text] [Related]
32. Lack of association between serum 25-hydroxyvitamin D levels and cervical human papillomavirus infection in systemic lupus erythematosus.
García-Carrasco M; Mendoza-Pinto C; Munguía-Realpozo P; Rodríguez-Gallegos A; Vallejo-Ruiz V; Muñoz-Guarneros M; Méndez-Martínez S; Soto-Santillán P; Pezzat-Said E; Reyes-Leyva J; López-Colombo A; Ruiz-Argüelles A; Cervera R
Lupus; 2015 May; 24(6):606-12. PubMed ID: 25411259
[TBL] [Abstract][Full Text] [Related]
33. Human papilloma virus and lupus: the virus, the vaccine and the disease.
Segal Y; Calabrò M; Kanduc D; Shoenfeld Y
Curr Opin Rheumatol; 2017 Jul; 29(4):331-342. PubMed ID: 28394823
[TBL] [Abstract][Full Text] [Related]
34. Colposcopic performance in a birth cohort previously eligible for human papillomavirus vaccination.
Sahlgren HAI; Elfgren K; Sparen P; Elfstrom MK
Am J Obstet Gynecol; 2022 May; 226(5):704.e1-704.e9. PubMed ID: 34954217
[TBL] [Abstract][Full Text] [Related]
35. Determinants of Cervical Cancer Screening Patterns Among Women With Systemic Lupus Erythematosus.
Chung SH; Oshima K; Singleton M; Thomason J; Currier C; McCartney S; Singh N
J Rheumatol; 2022 Nov; 49(11):1236-1241. PubMed ID: 35970535
[TBL] [Abstract][Full Text] [Related]
36. HIV-1, HIV-2, human papillomavirus infection and cervical neoplasia in high-risk African women.
Langley CL; Benga-De E; Critchlow CW; Ndoye I; Mbengue-Ly MD; Kuypers J; Woto-Gaye G; Mboup S; Bergeron C; Holmes KK; Kiviat NB
AIDS; 1996 Apr; 10(4):413-7. PubMed ID: 8728046
[TBL] [Abstract][Full Text] [Related]
37. Risk of systemic lupus erythematosus in patients with human papillomavirus infection: a population-based retrospective cohort study.
Shi LH; Huang JY; Liu YZ; Chiou JY; Wu R; Wei JC
Lupus; 2018 Dec; 27(14):2279-2283. PubMed ID: 30451639
[TBL] [Abstract][Full Text] [Related]
38. Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-point-registry-based follow-up of
Lehtinen M; Lagheden C; Luostarinen T; Eriksson T; Apter D; Harjula K; Kuortti M; Natunen K; Palmroth J; Petäjä T; Pukkala E; Siitari-Mattila M; Struyf F; Nieminen P; Paavonen J; Dubin G; Dillner J
BMJ Open; 2017 Aug; 7(8):e015867. PubMed ID: 28821519
[TBL] [Abstract][Full Text] [Related]
39. Immunogenicity and safety of a quadrivalent human papillomavirus vaccine in patients with systemic lupus erythematosus: a case-control study.
Mok CC; Ho LY; Fong LS; To CH
Ann Rheum Dis; 2013 May; 72(5):659-64. PubMed ID: 22589375
[TBL] [Abstract][Full Text] [Related]
40. Progression from human papillomavirus (HPV) infection to cervical lesion or clearance in women (18-25 years): Natural history study in the control arm subjects of AS04-HPV-16/18 vaccine efficacy study in China between 2008 and 2016.
Welby S; Rosillon D; Feng Y; Borys D
Expert Rev Vaccines; 2022 Mar; 21(3):407-413. PubMed ID: 34939897
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
